Rx Analytic

Starting Something New

The idea behind Rx Analytic (RxA) was relatively simple. Nano-encapsulate inhalable drug particles to achieve a constant aerodynamic diameter, control of pharmacokinetics, and pharmaceutical stability. These attributes allow for highly efficient and targeted drug delivery to specific regions of pathology in the lungs, local treatment with medication that would otherwise need systemic delivery, and room temperature storage for oligonucleotides. The platform was being co-optimized with a dry powder inhaler.

While successful in-silico, RxA was not funded for pre-clinical development. The wonderful thing about accepting reality and keeping an open mind about change is the opportunity this creates to do something new. For those who are interested it, RxA’s original landing page can be found here and its founder can be contacted through linkedin.